Dataset Information


Inhibition of N-myc expression sensitizes human neuroblastoma IMR-32 cells expressing caspase-8 to TRAIL.

ABSTRACT: OBJECTIVES:This study aims to explore the roles of N-myc and caspase-8 in TRAIL-resistant IMR-32 cells which exhibit MYCN oncogene amplification and lack caspase-8 expression. MATERIALS AND METHODS:We established N-myc-downregulated IMR-32 cells using shRNA lentiviral particles targeting N-myc and examined the effect the N-myc inhibition on TRAIL susceptibility in human neuroblastoma IMR-32 cells expressing caspase-8. RESULTS:Cisplatin treatment in IMR-32 cells increased the expression of death receptor 5 (DR5; TRAIL-R2), but not other receptors, via downregulation of NF-?B activity. However, the cisplatin-mediated increase in DR5 failed to induce cell death following TRAIL treatment. Furthermore, interferon (IFN)-? pretreatment increased caspase-8 expression in IMR-32 cells, but cisplatin failed to trigger TRAIL cytotoxicity. We downregulated N-myc expression in IMR-32 cells using N-myc-targeting shRNA. These cells showed decreased growth rate and Bcl-2 expression accompanied by a mild collapse in the mitochondrial membrane potential as compared with those treated with scrambled shRNA. TRAIL treatment in N-myc-negative cells expressing caspase-8 following IFN-? treatment significantly triggered apoptotic cell death. Concurrent treatment with cisplatin enhanced TRAIL-mediated cytotoxicity, which was abrogated by an additional pretreatment with DR5:Fc chimera protein. CONCLUSIONS:N-myc and caspase-8 expressions are involved in TRAIL susceptibility in IMR-32 cells, and the combination of treatment with cisplatin and TRAIL may serve as a promising strategy for the development of therapeutics against neuroblastoma that is controlled by N-myc and caspase-8 expression.


PROVIDER: S-EPMC6536445 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2011-01-01 | S-EPMC3234758 | BioStudies
2019-01-01 | S-EPMC6904486 | BioStudies
2018-01-01 | S-EPMC5943323 | BioStudies
2017-01-01 | S-EPMC5709619 | BioStudies
1000-01-01 | S-EPMC3887848 | BioStudies
1000-01-01 | S-EPMC4554544 | BioStudies
2011-01-01 | S-EPMC3255792 | BioStudies
1000-01-01 | S-EPMC2527645 | BioStudies
1000-01-01 | S-EPMC3041935 | BioStudies
2019-01-01 | S-EPMC6337360 | BioStudies